Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

First clinical experience with citrate-anticoagulated CVVHD-based low-flow ECCO<sub>2</sub>R in severe hypercapnic respiratory failure.

The International journal of artificial organs·2026

Same author

Activin signaling inhibitor Sotatercept in pulmonary veno-occlusive disease: building a bridge to transplantation?

Respiratory medicine case reports·2026

Same author

[Mechanisms of dyspnea].

Pneumologie (Stuttgart, Germany)·2026

Same author

Sex-Specific Phenotypes and Outcomes in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease: Results from the INSIGHTS-ILD Registry.

Respiration; international review of thoracic diseases·2026

Same author

Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysis.

ERJ open research·2026

Same author

Follow-up algorithm for detecting chronic sequelae of pulmonary embolism: diagnostic performance and possible limitations.

Journal of thrombosis and haemostasis : JTH·2025

Search research articles

Related Experiment Video

Updated: May 15, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Pulmonary hypertension in COPD.

Matthias Held¹, Berthold H Jany

¹Department of Internal Medicine, Medical Mission Hospital, Julius Maximilian Universität Würzburg, Würzburg, Germany. Matthias.held@missioklinik.de

Respiratory Care

|December 22, 2012

Summary

This summary is machine-generated.

Bosentan improved pulmonary hypertension (PH) in COPD patients. Long-term treatment showed significant gains in 6-minute walk distance, suggesting longer trial follow-ups are needed for COPD-related PH.

Keywords:

COPD clinical trials follow-up hemodynamics pulmonary hypertension treatment vasoactive drugs

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Related Experiment Videos

Last Updated: May 15, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Area of Science:

Pulmonary Medicine
Cardiology
Pharmacology

Background:

Pulmonary hypertension (PH) frequently complicates chronic obstructive pulmonary disease (COPD).
Vasoactive treatments are being explored for PH in COPD, but no drugs are currently approved.
Existing clinical trials for PH treatments often use short follow-up periods (12-16 weeks).

Purpose of the Study:

To evaluate the efficacy and safety of bosentan in patients with COPD-associated PH.
To assess the long-term effects of bosentan on exercise capacity and hemodynamics in this patient population.
To determine if shorter trial durations underestimate treatment benefits in COPD-related PH.

Main Methods:

Case series of 4 subjects with COPD and persistent PH despite optimized management.
Exclusion of other causes of PH, such as pulmonary embolism.
Treatment with bosentan, with monitoring of pulmonary artery pressure and 6-minute walk distance.

Main Results:

Bosentan treatment led to improvements in mean pulmonary artery pressure.
Significant average gains in 6-minute walk distance were observed at 2-3 months (36m) and 8-9 months (145m).
Individual patients experienced maximum gains up to 18 months, with stable oxygenation and no reported side effects.

Conclusions:

Bosentan may be a beneficial treatment option for select patients with COPD-associated PH.
Longer follow-up periods are crucial in clinical trials to accurately assess the therapeutic effects of vasoactive drugs in COPD-related PH.
Current trial durations of 16 weeks may underestimate the full treatment potential.